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Osteoblast-like UMR 106.06 cells respond to extracellular apphcation of nucleotrdes wtth a fast mtracellular calcium pulse (latency of about 20 
s. half-width of about 10 s), as measured with fluo-3 on a confocal laser scannmg system. Cross-inhibttion expertments at 50 FM show that, on 
a cell population basts, adenosine triphosphate (ATP) strongly mhibtts the effect of uridine triphosphate (UTP) or 2-methylthio-ATP (7-MeSATP) 
applied withm 2 mm after the end of the ATP-induced pulse, whtle prtor apphcatton of UTP or 2-MeSATP only weakly mhlbtts the ATP effect, 
and UTP and 2-MeSATP weakly mhtbtt each other. Furthermore. there are clear dtfferences m cross-mhtbmon responses between mdtvtdual cells. 
Our measurements provide strong evidence that these cells have at least two types of purino/nucleotide receptors, probably P?, and P,,. utth a 
proportion that vanes between indivtdual cells 
OsteobIast: ATP; Furiner~l~ receptor: Nucleottde receptor. lntr~cellular calcmm: Cross-lnhlbttlon 
1. INTRODUCTION 
Recently adenosine triphosphate (ATP) receptors in 
osteoclasts [I] and osteoblastic cells [2-4] have been 
reported. ATP receptors are classified as P, purinergic 
receptors and have been extensively studied in recent 
years in other types of cells [5-91. Studies of Pzy purino- 
ceptor mediated Ca2+ mobilization found that ade- 
nosine diphos~hate (ADP) was equipotent to ATP in 
rat hepatocytes, turkey erythrocytes, and bovine endo- 
thelial cells [lO--121, while non-adenosine nucleotides 
were generally inactive or much less potent than ATP. 
In other cells such as NCB-20 mammalian neuronai 
cells 191, human neutrophils/monocytes [13], and HL-60 
human leukemia cells [14], ADP was much less potent 
than ATP, while uridine triphosphate (UTP) was equal 
or more potent than ATP. These data suggested a recep- 
tor subtype that some workers called P1,, [6,9] and oth- 
ers called the ‘nucleotide receptor’ [ 15,161. 
UMR 106.06 is an osteosarcoma cell line with many 
characteristics of the osteoblast, including alkaline 
phosphatase activity, production of type I collagen, and 
response to parathyroid hormone with an elevation of 
intrac#lular cyclic adenosine monophosphate (CAMP) 
[1’7,18] and intracellular free calcium ([Ca’“],) [19]. Here 
we report novel cross-inhibition experiments with nu- 
cleotides, using a laser scanning imaging system that 
allows the response of individual cells to be seen. The 
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differences we observe in cross-inhibition between indi- 
vidual cell demonstrate that these cells have a mixed 
population of purino/nucleotide receptors. 
2. MATERIALS AND METHODS 
UMR 106.06 cells were cultured in Dulbecco’s modified Eagle’s 
Medium with high glucose (Gibco. Ltfe Technologtes Inc Grand 
Island, NY) supplemented with 10% fetal bovine serum (FBS; Flow 
Laboratories, McLean, VA) and anttbiottcs (100 @/ml pemcillin G. 
50 ,@ml gentamycm. and 2.50 ng/ml amphoterrcm B). Experiments 
were conducted two to three days after subculture, at which time the 
cells were confluent in 60-mm culture dishes (* 8 x IO’ cells/dish). 
Cells used are between passages 13-13. 
2.2. Reugmrs 
All chemtcals used were obtamed from Sigma except Z-methylthio- 
ATP (2-MeSATP). which was purchased from Research Btochemicals 
Inc. (Natick, MA). 
For fluorescence measurements of [Ca’*],% the celis were loaded wrth 
fluo-3iAM (6 pM) at 21°C for about 60 min. and then thoroughly 
washed, accordmg to the method of Kao et al [ZO] Measurements 
were carrted out at 37 rt 1°C. in a-mmimum essenttal medium with 25 
mM HEPES buffer replacmg bicarbonate, with 10 ml of medium per 
dish [l]. The laser scanner and detectors were attached to a Ntkon 
Optrphot microscope III a Bio-Rad MRC 600 confocal system. Com- 
plete images were digittzed and collected every 5 s Fluorescence mten- 
stty ttme courses for indivtdual cells or groups of cells were obtamed 
with the Optimas Image analysts program. 
3. RESULTS 
ATP induces a large, transient increase in [Ca”‘], in 
UMR 106.06 cells (Fig. 1A). At 25 PM, the time be- 
tween application of ATP to the bathing medium and 
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Fig. 1. Time courses of fluorescence intensity averaged over a group of UMR 106 06 cells (about 60 cells). showing typical responses to two 
applications of (A) ATP, (B) 2-MeSATP, (C) UPT, and to one application of (D) AMP-PCP. The results are representative of three or four 
experiments (separate dishes) for each nucleottde or ATP analog. 
the increase in fluorescence intensity to half maximum 
(T,,, is 39 ? 7 s (mean zt S.E.M.. 6 measurements). The 
duration of the transient, between attaining the half 
maximum intensity and declining to the half maximum 
(T,), is 16 rt 5 s. The magnitude of the calcium pulse in 
terms of AFfF = (Fpeak - F~~*~~F~~~~~~ where Fpeak is the 
peak fluorescence intensity after, and Fbefore is the fluo- 
rescence intensity just before application of extracellu- 
lar ATP, is 1.7 ? 0.5. At 50 ,uM this measure increases 
to 4.X rt 0.9 (n = 12: Fig. 1A; Table I). ADP, ‘-Me- 
SATP and UTP at 50 FM also produce a transient 
increase in [Ca”], (Fig. 1B.C; Table I). ~,~-methylene- 
ATP (AMP-PCP: Fig. 1D) and adenosine produce no 
discernable [Ca”], increase (100 PM, three or four 
measurements each). The rank-order at 50 PM in terms 
of AFIF is ATP > ADP = 2-MeSATP > UTP (Table I). 
We call this the ‘fluorescence intensity order’, which 
defines the ‘fluorescence intensity potency’. 
At 50 AM, a second dose of the same agonist applied 
within two minutes after the return of the first pulse to 
baseline, with no change in bathing medium, produces 
a negligible effect on [Ca”‘], with ATP and 2-MeSATP 
(n = 3 each; Fig. IA,B), or a smaller pulse in the case 
of UTP (Fig. 1C; ratio of AFlF values = 0.40 & 0.20, 
n = 3). After 10 min. a second application of ATP does 
produce a small pulse (ratio of AFIF values = 
0.35 + 0.11, n = 4). 
In terms of the response of the majority of the cells 
observed in each experiment, application of 50 FM ATP 
strongly inhibits the effect of 50 FM UTP or 50 PM 
210 
2-MeSATP applied within two minutes after the ATP- 
induced pulse returns to the baseline, with no change of 
medium (n = 3 each; Fig. 2). However, prior application 
of UTP or 2-MeSATP only weakly inhibits the ATP- 
induced effect (PI = 3 each: Fig. 3A,B). Prior application 
of UTP weakly inhibits the 2-MeSATP effect (n = 4; 
Fig. 3C) and the inhibitory effect of 2-MeSATP on 
subsequent application of UTP varies from partial inhi- 
bition (n = 5) to very little inhibition (n = 3; Fig. 3D). 
In many of these cross-inhibition experiments, a num- 
ber of individual ceils can be seen in respond differently 
from the majority of the cells in the given experiment. 
In almost all experiments where the majority of cells 
respond to both the first and second agonist, there are 
almost always cells that respond to the first agonist but 
not to the second, and other cells that do not respond 
Table I 
[Ca”], Increase in UMR 106 06 cells Induced by extracellular nucleo- 





ATP ADP 2-MeSATP UTP 
12 3 9 7 
21 k6s 25 415s 13 +2s 17 k3s 
9 f2s 8 k 3s 11 +4s 20 t5s 
4.8 2 09 39k 1.4 3.0 + 0.5 1.9 + 0.4 
Data expressed as mean f S E.M. 
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Fig. 2. Time course of fluorescence intensity averaged over a group of cells (about 60 cells), showing that application of ATP virtually abohshes 
the effect of (A) UTP or (B) 2-MeSATP applied withm two min after the ATP-induced pulse returns to the baseline. 
to the first agonist but do respond to the second (Fig. than in the osteoclast, of the signaling pathway leading 
3). In those experiments where the majority of cells to Ca2’ release, or it may reflect a longer period of time 
show that the ffect of the second agonist is inhibited needed for refilling of the intracellular Ca’+ pools linked 
by the first agonist, there are almost always cells that to the receptors activated by ATP. Mechanical perturba- 
do not show such inhibition, or even cells that do not tion experiments with osteoblastic cells found that a 
respond to the first agonist but do respond to the sec- second mechanical perturbation required more than a 
ond. three minute wait to induce a second calcium pulse [21]. 
In Ca’+-free bathing medium, the ATP effect is abol- 
ished at 25 PM in 3 of 5 measurements, at 50 PM in 2 
of 4 measurements, and at 100 PM in 1 of 3 measure- 
ments. In the experiments in which ATP induces a cal- 
cium pulse in the Ca2+-free medium. the Tl,2 is longer and 
the T, is much shorter than in normal bathing medium 
at equal ATP concentrations. 
4. DISCUSSION 
UMR 106.06 cells respond to extracellular ATP with 
a large, transient increase in [Cal’],. showing that this 
cell line has ATP receptors in the plasma membrane. 
We do not see two phases of [Ca”], increase as reported 
by Kumagai et al. [2]. Ca’+-free medium blocks the 
increase in [Ca”], in response to ATP in some but not 
all experiments, indicating that internal release of Ca” 
is involved, but that the Ca” influx is important in 
modulating the internal release. The lack of Ca’+ influx 
in Ca’+-free medium should reduce the steady-state cy- 
tosolic [Ca2’],. Ca”-free medium also prevents Ca’+ in- 
flux following ATP binding. Both of these effects should 
make internal release of Ca” more difficult. 
In contrast to osteoclasts [l], a second application of 
ATP within two minutes after the first calcium pulse 
returns to the baseline, with no change in bathing me- 
dium, does not produce another calcium pulse. With 
our volume of bathing medium per cell, and reported 
rates of hydrolysis of extracellular ATP by osteoblastic 
cells [3], we estimate that less than 5% of the applied 
ATP would be hydrolyzed during the 10 min following 
the first calcium pulse. The partial recovery of the cal- 
cium response to the second ADP application after 10 
min may thus reflect an adaptation, which is slower 
Classification of P, purinoceptors is largely based on 
rank-order of potency of the agonists because of the 
lack of selective, competitive receptor antagonists 
[6,15]. It has been reported that for P?Y receptors, the 
potency order defined on the basis of receptor-agonist 
affinity is 2-MeSATP >> ATP = ADP > AMP-PCP, 
UTP, while for PZX the affinity order is AMP- 
PCP >> ATP = 2-MeSATP > UTP [8,15,16]. Recent re- 
ports have shown another receptor subtype, named the 
P?, or the ‘nucleotide receptor’ [6,9-l 5,161 for which 
agonists elicit an increase in [Ca”], with the affinity 
order UTP = ATP > ADP > 2-MeSATP > AMP-PCP 
[15,16]. Since UTP induces a calcium pulse in UMR 
106.06 cells, it seems likely that these cells have some P?u 
nucleotide receptors. However, the receptors can’t be 
just P,,. or else the response to UTP should be greater 
than the response to ATP at 50 ,uM [9]. That 2-MeSATP 
produces a greater fluorescence intensity change than 
UTP suggests that there are Ply receptors. ATP could 
produce the greatest fluorescence intensity change 
among the agonists tested because 2-MeSATP, even 
though it has a greater affinity for the P,, receptor than 
does ATP, is only a partial agonist of this receptor 
[9,16,22,23], and so it would not be expected to produce 
as large an effect as ATP at 50 PM. Because it is con- 
ceivable that UTP could have an affect on PZY receptors, 
we cannot rule out the possibility of having only PzY 
receptors on the basis of the fluorescence intensity 
order. 
Another purinergic receptor known to be affected by 
agonists at these concentrations is the PZT. However, the 
P,, receptor has been found to have no response to ATP 
at concentrations up to 1 mM, and no response to UTP 
up to at least 100 ,LLM [24]. We cannot rule out the 
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Fig. 3. Fluorescence intenstty tmages of UMR 106 06 cells, showing the cross-inhibttion effect of (A) UTP (first pair. before and 20 s after 
apphcation) on ATP (last pair, before and 15 s after application) with an interval of 120 s between apphcations: (B) 2-MeSATP (first patr, before 
and 10 s after application) on ATP (last pair. before and 25 s after apphcatton) with an Interval of 110 s between apphcations; (C) UTP (first patr. 
before and 15 s after application) on 2-MeSATP (last patr, before and 10 s after apphcatton) with an Interval of 150 s between apphcations; and 
(D) 2-MeSATP (first pair, before and 50 s after apphcatron) on UTP (last pair. before and 20 s after apphcatton) wrth an Interval of 160 s between 
apphcations. The second agonist is applied within two mm after the return to the baseline of the first agonist-induced pulse. These trme sequences 
of images are representative of at least three experiments for each permutation of agomsts. Concentrattons are all 50pM. The scale bar is 50 PM. 
t 
possibility of having PzT receptors, but they would have 
no role in our measured responses to ATP and UTP. 
Our finding, that application of an agonist greatly 
inhibits the effect of the same agonist applied within two 
min after the first calcium pulse returns to baseline, 
suggested to us that, if there is only one receptor type, 
application of a different agonist at the same concentra- 
tion with the same or lower fluorescence intensity po- 
tency than the first should produce little response. Ap- 
plication of an agonist with a greater fluorescence inten- 
sity potency at the same concentration should elicit a 
response, if the Ca” pools have not been exhausted. On 
the other hand, if there is more than one receptor type 
present. then an agonist should have little inhibitory 
effect on a second agonist that is lower in the fluores- 
cence intensity order if the second agonist has a greater 
effect than the first on one of the receptor types, and if 
the Ca2+ pools linked to that receptor type have not 
been depleted. 
For populations of UMR 106.06 cells, our cross-inhi- 
bition experiments show that ATP greatly inhibits 2- 
MeSATP and UTP, but 2-MeSATP weakly inhibits 
ATP and partially or weakly inhibits UTP, and UTP 
weakly inhibits ATP and 2-MeSATP. From these cross- 
inhibition experiments we can establish a cross-inhibi- 
tion order, in which prior application of an agonist can 
significantly inhibit the response to another agonist that 
is lower in the order, but not the response to one that 
is equal or higher in the order. For our cell populations, 
we thus have ATP > 2-MeSATP ^- UTP. These data 
suggest that the receptors cannot be entirely P,,. other- 
wise UTP should inhibit ATP and 2-MeSATP. These 
data also suggest that the receptors cannot be entirely 
PzY either, or else 2-MeSATP at this fairly high concen- 
tration should inhibit the effect of UTP and of ATP. 
However, since 2-MeSATP is known to be only a partial 
agonist of the PzY receptor, it is conceivable that ATP 
or perhaps even UTP at this concentration could have 
an effect on PzY receptors even if the receptors were 
already saturated with 2-MeSATP. 
Our cross-inhibition experiments also show that indi- 
vidual cells can have different responses to the agonists, 
and thus would have different individual cross-inhibi- 
tion orders. For example, if one cell has little or no 
response to the application of ATP, but had a strong 
response to the prior application of UTP, while another 
cell in the same experiment has a stronger response to 
the application of ATP than to the prior application of 
UTP, then the first cell has a cross-inhibition order with 
UTP > ATP. while the second cell has a cross-inhibition 
order with ATP 2 UTP. Our cross-inhibition experi- 
ments show that some cells clearly respond more to 
ATP than to the prior application of UTP, others 
clearly respond more to UTP than to the subsequent 
application of ATP (with some not responding at all to 
ATP). and some respond strongly to both (Fig. 3A). 
Moreover, some cells respond more to ATP than to the 
prior application of 2-MeSATP. some respond more to 
2-MeSATP than to the subsequent application of ATP, 
and others respond about equally to both (Fig. 3B). 
There are also individual cells that respond more to 
UTP than to the prior application of 2-MeSATP, and 
others that respond more to the 2-MeSATP (Fig. 3D). 
These observations show that there are differences in 
cross-inhibition order between individual cells. The sim- 
plest explanation for these differences is that there is 
more than one type of receptor, with individual cells 
having a different portion of each receptor type. 
In summary, our data show that osteoblast-like 
UMR 106.06 cells respond to extracellular ATP, ADP, 
2-MeSATP and UTP with a [Ca”], pulse. Our cross- 
inhibition experiments provide strong evidence for a 
mixed population of purino/nucleotide receptors in 
these cells, most likely P,, purinoceptors and Pz,, nucle- 
otide receptors. with differences between individual cells 
in the proportion of these receptors. 
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